Compare iShares 20 Plus Year Treasury Bond ETF (TLT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 20 Plus Year Treasury Bond ETF vs Twist Bioscience Corp — how do they compare? iShares 20 Plus Year Treasury Bond ETF trades at $77.9 (market cap $47.61B), while Twist Bioscience Corp trades at $153.4 (market cap $10.08B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 4.7× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 20 Plus Year Treasury Bond ETF for 83 Days and Twist Bioscience Corp for 27 Days on average.
| TLT | TWST | |
|---|---|---|
Market Cap | $47.61B | $10.08B |
Volume | 49,263,490 | 4,229,037 |
Sector | Fixed Income | Health |
52-Week High | $92.06 | $205.00 |
52-Week Low | $77.11 | $25.45 |
Typical Hold Time | 83 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.145, down 0.17% amid a challenging bond market environment. The technical picture is bearish with moving averages signaling strong selling pressure, though oscillators are neutral. Recent news highlights Treasury yields reaching multi-decade highs, with the fund experiencing significant outflows and declining nearly 50% over five years as rising interest rates pressure long-duration bonds.
The outlook remains pressured by persistent high interest rates and inflation concerns. While current yields above 5% offer income appeal, further rate hikes or prolonged elevated rates could extend the downtrend. Key risks include Federal Reserve policy uncertainty and economic data volatility. Investors should weigh the income potential against continued price depreciation risk in the current macro environment.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
